Drug Profile
TS 23
Alternative Names: DS-9231; Stromab; TS23Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Translational Sciences
- Developer Daiichi Sankyo Company; Translational Sciences
- Class Anti-ischaemics; Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Antiplasmin inhibitors; Fibrinolytic agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pulmonary embolism; Stroke
- Phase I Myocardial infarction; Venous thrombosis
- No development reported Thrombosis
Most Recent Events
- 18 Mar 2024 Translational Sciences initiates enrolment in a phase II SISTER trial for Stroke in USA (NCT05948566)
- 18 Jul 2023 Translational Sciences plans a phase II SISTER trial for Stroke in unknown location (NCT05948566)
- 24 May 2023 Phase-II clinical trials in Pulmonary embolism in USA (IV) (CSL Behring pipeline, November 2022) (NCT05408546)